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Cantagalo virus (CTGV) is the etiologic agent of a pustular disease in dairy cows and dairy workers in Bra-
zil with important economical and occupational impacts. Nevertheless, no antiviral therapy is currently
available. ST-246 is a potent inhibitor of orthopoxvirus egress from cells and has proved its efﬁcacy in cell
culture and in animal models. In this work, we evaluated the effect of ST-246 on CTGV replication. Plaque
reduction assays indicated that CTGV is 6–38 times more susceptible to the drug than VACV-WR and
cowpox virus, respectively, with an EC50 of 0.0086 lM and a selective index of >11,600. The analysis of
b-gal activity expressed by recombinant viruses in the presence of ST-246 conﬁrmed these results. In
addition, ST-246 had a greater effect on the reduction of CTGV spread in comet tail assays and on the pro-
duction of extracellular virus relative to VACV-WR. Infection of mice with CTGV by tail scariﬁcation gen-
erated primary lesions at the site of scariﬁcation that appeared less severe than those induced by VACV-
WR. Animals infected with CTGV and treated with ST-246 at 100 mg/kg for 5 days did not develop pri-
mary lesions and virus yields were inhibited by nearly 98%. In contrast, primary lesions induced by
VACV-WR were not affected by ST-246. The analysis of F13 (p37) protein from CTGV revealed a unique
substitution in residue 217 (D217N) not found in other orthopoxviruses. Construction of recombinant
VACV-WR containing the D217N polymorphism did not lead to an increase in the susceptibility to ST-
246. Therefore, it is still unknown why CTGV is more susceptible to the antiviral effects of ST-246 com-
pared to VACV-WR. Nonetheless, our data demonstrates that ST-246 is a potent inhibitor of CTGV repli-
cation that should be further evaluated as a promising anti-CTGV therapy.
 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Cantagalo virus (CTGV) was isolated during an outbreak of a
pustular skin disease affecting dairy cows and milkers in the Rio
de Janeiro state of Brazil. The virus was characterized as a strain
of vaccinia virus (VACV; Orthopoxvirus; Poxviridae) and it shares
important genotypic and phenotypic features with the smallpox
vaccine used in Brazil until the late 1970s (Damaso et al., 2000).
Most outbreaks of CTGV-like infections have been reported in
Southeastern Brazil (Damaso et al., 2007; de Souza Trindade
et al., 2003; Megid et al., 2008; Nagasse-Sugahara et al., 2004),
but the spread of the disease in cattle and humans and its estab-
lishment in northern states in the Amazon biome has been de-scribed recently (Medaglia et al., 2009; Quixabeira-Santos et al.,
2011).
Infected animals develop pustular lesions on the teats and ud-
der, accompanied by fever and sometimes secondary mastitis.
Dairy workers usually acquire the disease during milking activities,
developing lesions on hands and arms, with associated lymphade-
nopathy, fever, and prostration. Generalized infections are rarely
observed. Nevertheless, infected workers are incapable of working
for 3–4 weeks (Moussatche et al., 2008). The economical and occu-
pational aspects of this emerging zoonosis require attention be-
cause of the increasing number of affected animals and
individuals (Damaso et al., 2007; Medaglia et al., 2009; Moussatche
et al., 2008). Attack rates vary from 11% to 80% of the herd depend-
ing on the farm size and herd density. Farms with high animal den-
sity combined with poor sanitation conditions usually have the
highest rates (Donatele et al., 2007; Quixabeira-Santos et al., 2011).
There is no antiviral therapy commercially available to treat
CTGV-infected animals or humans. The emergence of other ortho-
poxvirus infections worldwide poses similar concerns, such as out-
breaks of monkeypox virus in Africa and cowpox virus infections in
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tion, complications following smallpox vaccination are still a prob-
lem (Golden and Hooper, 2011). Therefore, considerable efforts
have been recently invested towards the search for effective anti-
orthopoxvirus drugs.
ST-246 (Tecovirimat) is a synthetic, tricyclononene antiviral
compound being developed to treat pathogenic orthopoxvirus
infections of humans (Yang et al., 2005). ST-246 targets VACV
p37, a viral palmitoylated protein encoded by VACV-Cop F13L gene
and required for production of extracellular forms of virus. ST-246
prevents formation of a wrapping complex required for production
of egress competent virus particles by inhibiting interaction of p37
with components of late endosomal transport vesicle biogenesis
(Chen et al., 2009). The compound is orally bioavailable and pro-
tects multiple animal species from lethal orthopoxvirus challenge
(Duraffour et al., 2007, 2010; Quenelle et al., 2007; Smith et al.,
2009, 2011). Human clinical trials have shown that ST-246 is safe
and well tolerated in healthy human volunteers with pharmacoki-
netic parameters consistent with once per day dosing (Jordan et al.,
2008, 2010).
In the present study we have evaluated the antiviral effect of
ST-246 on Cantagalo virus replication in cell culture and in mice.
We show that ST-246 is more efﬁcient at inhibiting CTGV replica-
tion in vitro when compared with other VACV strains and cowpox
virus. In addition, ST-246 prevented the formation of lesions in
mice inoculated with CTGV using the tail scariﬁcation model.2. Materials and methods
2.1. Cells and viruses
BSC-40 cells (African green monkey kidney), RK-13 (rabbit kid-
ney) and BHK-21 (baby hamster kidney) were propagated in
monolayer cultures at 37 C in Dulbecco’s modiﬁed Eagle’s med-
ium (Invitrogen) supplemented with 5% heat-inactivated fetal bo-
vine serum, as described (Damaso and Moussatche, 1992).
Cantagalo virus reference isolate CM-01 (Damaso et al., 2000), clin-
ical samples of CTGV isolates (Damaso et al., 2007), VACV strains
IOC, Wyeth (Damaso et al., 2000), WR and cowpox virus strain
Brighton Red (CPXV) were available in the laboratory’s collection.
Recombinant viruses, expressing the E. coli b-galactosidase gene
under control of a VACV early/late promoter (p7.5) inserted into
the thymidine kinase locus, were constructed in our laboratory
(CTGV-bGal) or kindly provided by Dr. Peter Turner of the Univer-
sity of Florida (VACV-WR-bGal). The recombinant virus vvWR-GFP-
F13L in which the GFP gene replaces the WT F13L sequence was
described previously (Chen et al., 2009). Viruses were routinely
propagated and titered by plaque assay in BSC-40 cells, as de-
scribed (Damaso and Moussatche, 1992).
2.2. ST-246
ST-246 was synthesized and supplied by SIGA Technologies
(Corvallis, OR). The drug was dissolved in DMSO and was stored
at 20 C as a 10 mM stock solution.
2.3. Plaque reduction assay and cytopathic effect (CPE) reduction assay
BSC-40, RK13 or BHK-21 monolayers (1  106 cells per plate)
were infected with the indicated multiplicity of infection (MOI)
of CTGV or other orthopoxviruses. After a 90-min adsorption peri-
od, viral inocula were removed (Time zero; 0 h), the cells were
washed with phosphate buffered saline and were incubated with
medium with 0.01, 0.02, 0.05, 0.1, or 0.5 lM ST-246 or 0.1% DMSO
(vehicle). After 48 h post-infection, the cells were stained with 0.1%crystal violet, and the viral plaques were counted. For the 96-h as-
says and for experiments using recombinant VACV-WR expressing
mutated F13L, 1% 2-methylcellulose was added to the medium at
0 h. The percentage of inhibition of plaque formation was calcu-
lated as follows: 100  [(mean number of plaques in test  100)/
(mean number of plaques in control)]. The EC50 values (effective
concentration of drug required to inhibit 50% of virus replication)
were derived from the plots.
In some experiments, cytopathic effect reduction assays were
conducted to measure the effective concentration of compound
that inhibited 50% of the virus induced CPE. BSC-40 monolayers
were seeded in 96-well plates at 1  104 cells per well in 180 ll
of growth media. ST-246 was added directly to the assay plates
at 24 concentrations (0.001–5 lM) using the HP D300 digital titra-
tion instrument (Hewlett Packard, Corvallis, OR). Cell monolayers
were infected with wild-type vaccinia virus or the vaccinia virus
recombinants containing the D217N amino acid substitution using
an amount of virus that would cause 95% CPE at 3 days post-infec-
tion. The assay was terminated at 3 days post-infection by ﬁxing
the cells in 5% glutaraldehyde solution and the amount of CPE
was visualized by staining the monolayers with 0.1% crystal violet.
Virus-induced CPE were quantiﬁed by measuring absorbance at
570 nm. The EC50 values were calculated by ﬁtting the data to a
four-parameter logistic model to generate dose–response curve
using XLﬁt 4.1 (IBDS, Emeryville, CA).
2.4. Visualization of viral plaques and detection of b-galactosidase
activity in infected cells
Monolayers of BSC-40 cells (1  106 cells/well) were infected
with 200 PFUs of the recombinant viruses CTGV-bGal or VACV-
WR-bGal and cells were either treated with 0.01, 0.02 or 0.05 lM
ST-246 or with 0.05% DMSO (control). At 48 h post-infection, the
monolayers were ﬁxed with 4% paraformaldehyde, washed twice
with PBS 1 and incubated 18 h at room temperature with a solu-
tion containing 0.4 mg/ml X-Gal, 4 mM potassium ferrocyanide,
4 mM potassium ferricyanide, and 2 mM MgCl2 (Sanes et al.,
1986). The sites of enzyme activity were detected through the
visualization of blue viral plaques.
For measurement of b-galactosidase activity, the monolayers
were infected and treated with ST-246 as described above, and
after 48 h the cells were processed as described (Chakrabarti
et al., 1985). Cellular extracts were mixed vigorously with chloro-
form/SDS, and incubated with 4 mg/ml ONPG [O-nitrophenyl-B-D-
galactopyranoside] until a light yellow color was developed. The
samples were quantiﬁed at A420nm.
2.5. Comet tail inhibition assay
BSC-40 cells grown in 6-well plates (1  106 cells/well) were in-
fected with 50 PFU of CTGV or VACV-WR and either treated with
0.05% DMSO (control) or with different concentrations of ST-246.
The plates were incubated tilted at a 5 angle for 3–4 days at
34.6 C and then stained with 0.1% crystal violet. Comet tail forma-
tion in vehicle-treated group and ST-246 treated cells was com-
pared by visual inspection.
2.6. Determination of the production of intracellular and extracellular
virus
For evaluating the production of intracellular virus, BSC40 and
RK-13 cells were infected at a MOI of 0.001 for 2 h. After the
adsorption period, the virus inocula were removed, the cells were
washed and fresh medium was added to the monolayers. After 0,
24 and 48 h post-infection, the cells were harvested in sterile
water, and were submitted to three cycles of freezing and thawing.
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natively, in experiments to determine virus yield of recombinant
VACV-WR expressing mutated F13L, an MOI of 0.1 was used and
virus titers were determined after 24 h post-infection, as described
above.
For analysis of extracellular virus, BSC-40 monolayers were in-
fected with an MOI of 0.001 of CTGV or VACV-WR, and at the time
of infection (0 h) the cells were incubated in the absence or pres-
ence of ST-246 at different concentrations. After 48 h, the medium
was removed and centrifuged at 1000g for 10 min. Samples of fresh
supernatant were incubated with IMV-neutralizing monoclonal
antibodies directed against A28 protein kindly provided by Dr.
Chwan Foo of the University of Pennsylvania (Foo et al., 2009).
Antibody dilution was previously tested for neutralizing VACV-
WR and CTGV. After 1 h at 37 C, the yield of extracellular virus
particles was determined in the supernatant depleted of IMV by
plaque assay in BSC-40 cells. The values represent the mean of 3
independent experiments.2.7. Infection assays in mice
Groups of female BALB/c mice (nP 5; 5–7 weeks of age) were
anesthetized with a ketamine–xylazine mixture (100 and 6 mg/
kg, respectively). Samples of puriﬁed CTGV or VACV-WR
(1  106 PFU) diluted in 10 ll of PBS were deposited on the base
of the tail, followed by scariﬁcation with a 24-gauge needle (Mel-
amed et al., 2007). The animals were housed in ﬁlter-top microis-
olator cages. Treatment with different doses of ST-246 was
initiated 4 h post-infection by oral gavage and continued every
24 h for 7 days. Control animals were treated with the vehicle
(0.5% v/v Tween 80; 1% w/v hydroxypropylmethylcellulose) (Gro-
senbach et al., 2008; Yang et al., 2005). Mice were evaluated daily
for clinical signs of disease. For determination of virus yield, in-
fected mice were euthanized, and the primary lesions were re-
moved with a blade and kept in PBS at 80 C. The tissue was
frozen and thawed twice, ground in a tissue homogenizer, and
after low-speed centrifugation, the supernatant was used for deter-
mination of virus yield by plaque assay in BSC-40 cells. Protein
concentration was determined in a duplicate sample. All animal
experiments were performed according to the NIH Guidelines for
the Care and Use of Laboratory Animals, and the protocols were ap-
proved by the Animal Ethics Committee of the Centro de Ciências
da Saúde, Universidade Federal do Rio de Janeiro.2.8. F13L sequencing
For F13L sequencing, DNA samples from CTGV and VACV-IOC
were used as templates in PCR assays containing primers F13fwd
Ext (50-TAC GCA ATA TCT CAA TAG TTT CAT AAT TG-30) and
F13rev Ext (50-ATT GAC TGA GTT AGG TTG TG ATT CG-30) (Damaso
et al., 2000). Amplicons were puriﬁed using the Illustra GFX PCR
DNA and Gel Band Puriﬁcation kit (GE Healthcare, São Paulo, Bra-
zil) and sequenced by the Genomics Unit of the Instituto de Bioﬁ-
sica Carlos Chagas Filho-UFRJ. GenBank accession numbers for
CTGV and VACV-IOC are JX024889 and JX024890, respectively.
Multiple alignment of the predicted amino acid sequences of
F13L orthologs from different orthopoxviruses was generated by
BioEdit v. 5.0.9. Virus species and Genbank accession numbers
are as follows: VACV-WR (NC_006998); Cowpox-Brighton Red
(CPXV-BR; NC_003663); vaccinia virus-Lister (VACV-lst;
AY678276); VACV-MVA (U94848); VACV-LC16m8 (AY678275);
VACV-Copenhagen (VACV-Cop; M35027); monkeypox virus-Libe-
ria 1970 (MPXV-LBR70; DQ011156); horsepoxvirus MNR-76
(HSPV; DQ792504); variola virus-Garcia 1966 (VARV-GAR66;
Y16780); VARV-Banglsdesh-1974 (VARV-BGL74; DQ441422);ectromelia virus-Naval (ECTV-NAV; (PBR, 2012)); taterapox virus
(TATV; NC_008291); camelpox virus (CMLV; AY009089).
2.9. Construction of VACV recombinant virus
VACV-WR was used to construct a virus recombinant contain-
ing the D217N amino acid substitution in the F13L gene. Site direc-
ted mutagenesis was performed using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene, CA) with primers F13L-
D21N-F (50-TTG GGA TAT TCT AGA AAT CTA GAT ACC GAT-30)
and F13L-D217N-R (50-ATC GGT ATC TAG ATT TCT AGA ATA TCC
CAA-30) and plasmid pWR-F13L, that contains the F13L gene from
VACV-WR cloned into plasmid pCR2.1. The DNA from the recombi-
nant plasmid was sequenced to conﬁrm the presence of the D217N
mutation. The F13L gene containing the D217N mutation and
ﬂanking DNA was PCR ampliﬁed using a Platinum PCR SuperMix
High Fidelity PCR kit (Life Technologies, OR) and recombinant plas-
mid DNA with primers, CB129 (50-GCG ATA TAG CCG ATG ATA TTC-
30) and Vac3981 (50-CAT CCA TCC AAA TAA CCC TAG-30). The PCR
assay conditions were 30 cycles at 94 C for 20 s, 55 C for 20 s,
and 68 C for 2 min and the resulting PCR amplicon was puriﬁed
using a PCR puriﬁcation kit (Qiagen, CA). BSC-40 cells were seeded
into 6-well plates containing 7.5  104 cells/well in 2 ml of growth
media and the next day were infected with 0.1 PFU/cell of vvWR-
GFP-F13L which contains the GFP gene in place of the F13L coding
sequences (Chen et al., 2009). Following infection, the cells were
transfected with 500 ng of the PCR product encoding the mutated
F13L gene using lipofectamine with Opti-MEM media (Life Tech-
nologies, OR). The next day the cells were collected by scraping
into 0.5 ml PBS and lysed by repeated freeze–thaw cycles and
80 C and 37 C, respectively. The virus suspension was centri-
fuged at 1000g for 10 min at 4 C to remove cell debris. The virus
suspension was titered by plaque assay on fresh BSC-40 monolay-
ers using a 1% methylcellulose overlay. Plaques identiﬁed by
microscopy that did not exhibit green ﬂuorescence were isolated
and expanded in BSC-40 monolayers seeded in a 24-well plate.
The virus from these plaque isolates were puriﬁed by two addi-
tional rounds of plaque isolation. The F13L gene from the ﬁnal pla-
que isolates were ampliﬁed by PCR and sequenced to conﬁrm the
presence of the D217N amino acid change.
2.10. Statistical evaluations
Data presented in this work were expressed as mean ± SD (stan-
dard deviation). The results of one test group were compared to an-
other group and analyzed statistically with unpaired Student’s t-
test. The results of more than two sets of measurements in one
experiment were analyzed statistically by one-way analysis of var-
iance (ANOVA) followed by Dunnett’s and Tukey’s Multiple Com-
parison Tests. A p value <0.05 was considered statistically
signiﬁcant. All analyses were performed using Prism v 5.01 (Graph-
Pad Software, Inc.).3. Results
3.1. Replication of CTGV, VACV-WR and VACV-IOC in different cell lines
Previous results fromour group indicated that CTGVhas an over-
all lower dissemination rate and yield production in cell culture
when compared to other VACV strains (Damaso et al., 2000; Jesus
et al., 2009a). Therefore, we ﬁrst evaluated the growth rates of CTGV
and two other VACV strains in two different cell lines before further
testing the antiviral effect of ST-246 in these cell types.We observed
that in RK-13, BSC-40 and BHK-21, CTGV produced less infectious
particles than VACV-WR at 24 and 48 h post-infection (p < 0.01)
Fig. 1. Virus replication in RK-13, BSC-40 and BHK-21 cells. RK-13 (A), BSC-40 (B) and BHK-21 (C) cells were infected with CTGV, VACV-WR or VACV-IOC (MOI = 0.001). At
zero, 24 and 48 h post-infection, the monolayers were harvested for virus titration in BSC-40 cells. The values (±SD) represent the mean of 3 independent assays. Asterisks:
⁄⁄⁄p < 0.001, ⁄⁄p < 0.01, ⁄p < 0.05 (One-way Anova followed by Donnett’s and Tukey’s tests) when comparing CTGV or VACV-IOC with VACV-WR. Differences in yield between
CTGV and VACV-IOC were not statically signiﬁcant.
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cell lines tested (p > 0.05). Despite the lower rates of replication,
both CTGV and VACV-IOC were able to develop their replicative cy-
cle and produce virus particles over the course of infection in these
cells. All subsequent experiments were done in BSC-40 cells.
3.2. ST-246 inhibits CTGV replication in vitro
ST-246 has been previously evaluated for toxicity to BSC-40
cells (Yang et al., 2005). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)-based assays conﬁrmed that the
drug was not toxic to the monolayers revealing that
97.3 ± 13.94% of the cells were viable after 48 h in the presence
of 100 lM ST-246 (p > 0.05; Student’s t-test) (data not shown).
To evaluate the antiviral effect of ST-246 on the replication of
CTGV, we analyzed the formation of virus plaques in the presence
of the drug for 48 h. As shown in Fig. 2A, ST-246 inhibited CTGV
plaque formation at 48 h post-infection and this effect appeared
to be more dramatic than that observed for VACV strains IOC and
WR. Similar effects on plaque formation were observed at 96 h
post-infection (p < 0.001; one-way Anova followed by Tukey’s
tests) or when RK-13 or BHK-21 cells were infected with these
viruses (p < 0.01; one-way Anova followed by Tukey’s tests) (data
not shown). We extended the concentration range of ST-246 and
included other orthopoxviruses in the assay (Fig. 2B). The antiviral
effect of ST-246 was dose-dependent for all viruses tested, but
CTGV was signiﬁcantly more susceptible to the effect of ST-246
than other orthopoxviruses. At 0.02 lM ST-246, a 95.1% reduction
of virus plaque formation was measured for CTGV whereas an inhi-
bition of <40% in plaque formation was measured for all other
orthopoxviruses at this concentration (p < 0.001). The EC50 valuesobtained in infected BSC-40 cells are shown in Table 1. These val-
ues conﬁrmed that ST-246 was more potent at inhibiting CTGV
replication when compared with other orthopoxviruses
(p < 0.001). Based on the EC50 and CC50 values, the resulting selec-
tive index (SI; CC50/EC50) was estimated to be >11,600 for CTGV
and >1800 for VACV-WR.
CTGV was isolated in 1999, and during the past decade there
have been numerous reports of outbreaks of CTGV-like infections
in several states of Brazil (Damaso et al., 2007; Medaglia et al.,
2009; Megid et al., 2008; Nagasse-Sugahara et al., 2004). To inves-
tigate the response proﬁle of different CTGV isolates to ST-246, we
selected 15 clinical samples collected in three states of Brazil from
2000 to 2008, which were PCR-conﬁrmed as CTGV (Damaso et al.,
2007). The virus samples were tested for the formation of virus pla-
ques in the presence of different concentrations of ST-246. As ob-
served in Fig. 2C, similar dose–response curves were observed for
all CTGV isolates (p > 0.05). These data conﬁrmed the increased
susceptibility of all CTGV isolates to ST-246 when compared to
VACV-IOC (p < 0.01).
Viral plaques formed during CTGV infection at 48 h post-infec-
tion in the absence of compound were smaller than those formed
by VACV-WR (p < 0.001; Student’s t-test) (Fig. 2A). In the pres-
ence of ST-246, the plaque size was further reduced, consistent
with reports by others (Smith et al., 2009; Yang et al., 2005).
To better visualize plaque formation, we infected BSC-40 cells
with recombinant CTGV and VACV-WR expressing the b-galacto-
sidase gene under control of a viral early/late promoter in the
presence of increasing concentrations of ST-246. The average pla-
que numbers obtained in untreated monolayers were similar be-
tween CTGV and VACV-WR infections (p > 0.05; Student’s t-test).
In the presence of ST-246, we observed a dramatic reduction in
Fig. 2. Effect of ST-246 on virus plaque formation. BSC-40 cells were infected with approximately 200 PFU of CTGV, VACV-IOC or VACV-WR (A) in addition to the
orthopoxviruses cowpox, VACV-Wyeth (B) or several clinical isolates of CTGV (C), in the absence or presence of the indicated concentrations of ST-246. Viral plaques were
visualized by crystal violet staining after 48 h and manually counted. The values (±SD) represent the mean of at least 3 independent assays. (A) The average numbers of viral
plaques in untreated cells were 264 ± 38.5 for VACV-WR, 244.8 ± 46.84 for VACV-IOC and 215.28 ± 56.60 for CTGV (p > 0.05; one-way Anova followed by Tukey’s tests). (B and
C) Asterisks: ⁄⁄p < 0.01 or ⁄⁄⁄p < 0.001 (One-way Anova followed by Donnett’s and Tukey’s tests) when comparing CTGV and the other orthopoxviruses tested (B) or each
isolate of CTGV and VACV-IOC in the indicated concentration (C).
Table 1
EC50 and SI values of ST-246 for distinct orthopoxviruses.
Virus EC50 (lM)a CC50 (lM) Selective Index (SI)b
Cowpox 0.33 ± 0.025 >100 >303.03
VACV-WR 0.055 ± 0.003 >100 >1,818.18
VACV-Wyeth 0.046 ± 0.002 >100 >2,173.91
VACV-IOC 0.034 ± 0.006 >100 >2,941.17
CTGV 0.0086 ± 0.001c >100 >11,627.9
a The EC50 for each virus was estimated based on values obtained in
Fig. 1B ± standard deviations.
b The selective index for each virus was determined as the ratio CC50/EC50. The
values represent the mean of at least 3 independent assays.
c p < 0.001 (one-way Anova followed by Donnett’s and Tukey’s tests) relative to
other orthopoxviruses tested.
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whereas VACV-WR plaques were only slightly affected at these
concentrations (p > 0.05; Student’s tests) (Fig. 3A). We also mea-
sured b-galactosidase activity in infected cells as a direct evi-
dence of virus replication in the sites of plaque formation
(Fig. 3B). In the presence of ST-246, the enzyme activity in
CTGV-infected cells was signiﬁcantly reduced compared to
VACV-WR infected cells, with a maximal difference of nearly 8-
fold at 0.02 lM (p < 0.001). Taken together these results con-
ﬁrmed the increased susceptibility of CTGV to ST-246 when com-
pared with other orthopoxviruses.3.3. ST-246 inhibits the production of extracellular CTGV
ST-246 is reported to inhibit virus egress from infected cells,
reducing the production of extracellular viruses and the subse-
quent spread of infection (Duraffour et al., 2007; Yang et al.,
2005). To evaluate the effect of ST-246 on the production of extra-
cellular particles of CTGV, we performed a comet tail reduction as-
say. Comet tails are formed by secondary viral plaques generated
due to the efﬁcient spread of extracellular virus at long distances
from the primary site of replication (primary plaques). In untreated
cells, CTGV formed smaller comet tails compared to VACV-WR
(Fig. 4A). In the presence of increasing concentrations of ST-246,
comet tails were reduced for both viruses, demonstrating the clear
effect of ST-246 on extracellular virus production. Nevertheless, in
CTGV-infected cells, comet tails were barely detected at 0.015 lM
ST-246 whereas VACV-WR still generated small comets and pri-
mary plaques at 0.05 lM. This result suggested that the production
of extracellular particles in CTGV-infected cells was more suscepti-
ble to the effect of ST-246 than in cells infected with VACV-WR.
It is important to note that comet tails were visualized in CTGV-
infected cells after 4 days of infection, whereas VACV-WR comets
were better visualized after 3 days because of the difference in
the sizes of virus plaques. Therefore, to measure the effect of ST-
246 after similar period of treatment and infection, BSC-40 cells
were infected in the presence of different concentrations of ST-
246, and cell medium was harvested after 48 h. Medium samples
were ﬁrst depleted of contaminating IMV released from lysed cells
Fig. 3. Effect of ST-246 on b-galactosidase expression under control of a viral promoter. BSC-40 monolayers were infected with 200 PFU of recombinant CTGV and VACV-WR
expressing b-galactosidase in the presence of the indicated concentrations of ST-246. (A) After 48 h, the cells were ﬁxed and incubated with X-Gal for visualization of blue
plaques, as described. Representative images are shown. (B) Alternatively, the monolayers were collected in PBS and processed for detection of b-galactosidase in the
presence of ONPG, as described. The values (±SD) represent the mean of four independent assays. Asterisks: p < 0.001 (Student’s t-tests) when comparing CTGV to VACV-WR
at the indicated concentration of ST-246. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Production of extracellular virus in the presence of ST-246. (A) Comet tail assay: BSC-40 cells were infected with 50 PFU of CTGV or VACV-WR in the presence of the
indicated concentration of ST-246. The plates were placed under inclination of 5 during the incubation period. After 48 h, the cells were stained with crystal violet for
visualization of virus plaques and comet tails. The negative image of a representative assay is shown. (B) Yields of extracellular virus: BSC-40 cells were infected with CTGV or
VACV-WR (1000 PFU) either in the absence or presence of the indicated concentrations of ST-246, and the yields of extracellular virus in medium after 48 h was determined
by plaque assay. The values represent the mean (±SD) of three independent assays titrated in duplicate. Asterisks: p < 0.001 (Student’s t-tests) when comparing CTGV to
VACV-WR at the same concentrations of ST-246.
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Table 2
Data on the formation of lesions following animal infection and treatment with ST-246.
Groups No. animals with primary
lesionsa (infection rate)
Primary lesion
area ± SD (cm2)b
Primary lesionsc
Appearance/
Scab fall-off
Severity of primary
lesionsd
No. animals with secondary
lesionse (mean number
of lesions ± SD)
VACV-WR
vehicle
16/16 (100%) 0.42 ± 0.039 4–5 days/16–19 days +++++ 16/16 (8.19 ± 6.804)
VACV-WR
50 mg/kg ST-246
12/12 (100%) 0.41 ± 0.028 4–5 days/16–19 days ++++ 0/12 (0)
VACV-WR
100 mg/kg ST-246
12/12 (100%) 0.43 ± 0.039 4–5 days/12–14 days +++ 0/12 (0)
CTGV
vehicle
19/19 (100%) 0.42 ± 0.042 4–5 days/12–15 days ++ 2/19 (0.16 ± 0.501)f
CTGV
50 mg/kg ST-246
3/12 (25%) 0.40 ± 0.025 4–5 days/9–11 days ± 0/12 (0)
CTGV
100 mg/kg ST-246
0/12 (0%) – – _ 0/12 (0)
a Number of animals that developed primary lesions/number of infected animals.
b The differences between scab areas were not statistically signiﬁcant (p > 0.7; one-way Anova using Tukey’s test).
c Days post-infection when primary lesions were ﬁrst noticed and the scabs peeled off.
d The following clinical signs in the site of inoculation were scored to evaluate the severity of lesions: redness, swollen area, involvement of deeper tissues.
e Number of animals that developed secondary lesions/number of infected animals.
f p < 0.0001 (Student’s test) relative to VACV-WR (vehicle).
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sequently titrated on BSC-40 cells. As shown in Fig. 4B, ST-246
inhibited the production of infectious extracellular CTGV in a
dose–response way. Extracellular yield was inhibited by nearly
64% at 0.01 lM ST-246, whereas a decrease of approximately 4%
was detected for VACV-WR at this dose (p < 0.001). At 1 lM, the
yield of extracellular CTGV dropped 3logs when compared with a
2-log reduction for VACV-WR (p < 0.001).
3.4. ST-246 inhibits the formation of lesions in mice infected with CTGV
We next investigated the antiviral effect of ST-246 on the repli-
cation of CTGV in vivo. To determine the best route of infection for
producingmeasurable disease inmice, we tested intravenous injec-
tion into the tail vein, intranasal inoculation and scariﬁcation on the
tail. Intravenous inoculations of BALB/cmicewith up 5  104 PFU of
CTGV by the tail vein did not generate lesions on the tail in contrast
to inoculation with 5  103 PFU of VACV-WR, which produced vis-
ible lesions by day 13 post-infection (data not shown). Similarly,
intranasal inoculation of mice with 105 or 5  107 PFU of CTGV
did not produce clinical signs of disease in mice such as weight loss
(weight was measured daily for 21 days), rufﬂed fur or lethargy
(Reis, Moussatche and Damaso, unpublished data) whereas intra-
nasal inoculation of mice with 105 PFU of VACV-WR producedmea-
surable clinical disease with symptoms that have been used by
others to describe disease severity (Alcami and Smith, 1996; Bray
et al., 2000). In addition, CTGV yields were not detected in lungs, li-
ver or spleen of mice after intranasal infections with 105 PFU sug-
gesting that virus replication was localized to the site of infection
and rapidly cleared by the host (Reis, Moussatche and Damaso,
unpublished data). Nevertheless, the tail scariﬁcation model pro-
duced detectable lesions at the site of inoculation with CTGV and
it was selected for further evaluation of ST-246.
Mice were infected with 1  106 PFU of CTGV or VACV-WR by
scariﬁcation of the skin on the base of the tail. At 4 h post-infection,
the vehicle or 10, 25, 50 or 100 mg/kg ST-246 was administered by
oral gavage. Drug treatment continued every 24 h for 7 days. Vehi-
cle-treated animals infected with either virus developed primary
lesions of similar extent on the scariﬁed area after 4–5 days post-
infection (Table 2). However, lesions resulting from VACV-WR
infection were more severe and appeared to affect deeper tissues
than those developed in mice infected with CTGV (Table 2), as
determined by visual inspection at 7 and 9 days post-infection(Fig. 5A and F; details in Fig. 5K and M). In addition, infection with
VACV-WR generated secondary lesions (satellite lesions) on the
tail, which were rarely observed during CTGV infection (Table 2)
(Fig. 5A and K, arrows). Treatment with different doses of ST-246
had no effect on the extent of lesion formation (Table 2) and only
minor effects on the severity of primary lesions produced by VACV-
WR (Fig. 5A–E). Animals administered 100 mg/kg of ST-246, had
less severe lesions that resolved sooner relative to vehicle-treated
animals. (Table 2) (Fig. 5A, E, K and L). Nevertheless, as indicated in
Table 2, the generation of satellite lesions by VACV-WR was com-
pletely inhibited in animals treated with ST-246 (Fig. 5E; details in
Fig. 5L). On the other hand, the primary lesions produced by CTGV
infection were greatly reduced in severity by ST-246 treatment
(Fig. 5F–J; details in Fig. 5M and N). At 25 mg/kg of ST-246, the le-
sions on the tail were less severe than those in vehicle-treated
mice (Fig. 5H), and were not visible in animals treated with
100 mg/kg (Table 2) (Fig. 5J and N). Similar results were observed
when mice were evaluated up to 20 days post-infection (data not
shown). The infection of mice with 1  108 PFU of CTGV slightly in-
creased the severity of the lesions, but did not produce satellite le-
sions on the tail (Fig. 5O). Treatment with ST-246 at 100 mg/kg also
prevented primary lesion development with this elevated virus
dose (Fig. 5P).
To quantify the production of virus at the site of inoculation
after treatment with ST-246, the animals were euthanized at
5 days post-infection, and the primary lesions were excised and
processed for virus titration. Skin areas adjacent to the primary le-
sion were not removed because CTGV rarely induced satellite le-
sions along the tail in contrast to VACV-WR infection, which
produced measurable satellite lesions on the tail (Table 2). As ob-
served in Fig. 6, CTGV yields in the primary lesion were signiﬁ-
cantly reduced after treatment with 50 and 100 mg/kg ST-246.
The production of infectious particles was inhibited by
96.9 ± 9.77% and 98.4 ± 4.07%, respectively (p < 0.001). On the con-
trary, no signiﬁcant effect was observed in the production of VACV-
WR in the primary lesion (p > 0.05). This result conﬁrmed the in-
creased efﬁcacy of ST-246 against CTGV infection in vivo.
3.5. Sequence analysis of the F13L ortholog in CTGV
The protein F13 (p37) is encoded by F13L gene and has been
mapped as the target of ST-246 in distinct orthopoxviruses (Chen
et al., 2009; Duraffour et al., 2008; Yang et al., 2005). Analysis of
Fig. 5. ST-246 inhibits tail lesions induced by CTGV infection in mice. Female BALB/c mice (nP 5) were infected with 1  106 PFU of puriﬁed CTGV or VACV-WR (A–N) or
1  108 PFU of CTGV (O and P) by tail scariﬁcation. ST-246 treatment with the indicated doses was initiated 4 h post-infection by oral gavage and was repeated every 24 h for
7 days. Representative images of animals at 7 (A–J; N and O) and 9 days post-infection (K–N) are shown. Arrows point to secondary lesions.
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mutations and 1 missense substitution, which led to the insertion
of an asparagine replacing an aspartic acid in residue 217 of the
protein (D217N) (Fig. 7A). Based on the predicted amino acid se-
quence, F13 expressed by CTGV preserved the sites of palmitoyla-
tion, the HKD phospholipase motif involved in F13 function, the
YPPL motif required for efﬁcient release of extracellular virus,
and the G residue in position 277 involved in resistance to ST-
246. Nevertheless, the substitution D217N was speciﬁc to F13L
ortholog of CTGV and was not found in any other Orthopoxvirus
(Fig. 7A).
To investigate whether the D217N polymorphism in F13L gene
accounted for the increased susceptibility of CTGV to ST-246, re-
combinant VACV-WR were constructed expressing the F13 protein
containing the D217N amino acid substitution. The susceptibilityto ST-246 was evaluated by three different assays to measure the
effects on CPE, number of viral plaques and yield in the presence
of increasing concentrations of ST-246. As shown in Fig. 7B, two
isolates (#B and #C) of recombinant viruses expressing mutated
F13L were slightly less susceptible to ST-246 than VACV-WR
expressing WT F13L by CPE-reduction assays. This was conﬁrmed
by analysis of the EC50 values obtained from at least three indepen-
dent experiments (p < 0.01 for mutant #B and p < 0.001 for mutant
#C) (Table 3). Nevertheless, analysis of virus plaque formation in
the presence of ST-246 (Fig. 7C) and yield-reduction assays
(Table 3) indicated that both mutant viruses and wild-type
VACV-WR were equally susceptible to ST-246. Differences in the
EC50 values for virus yield and inhibitory values for plaque number
and virus yield at 0.05 lM ST-246 were not statistically signiﬁcant
(p > 0.05) (Table 3). Overall, these results suggest that the D217N
Fig. 6. Effect of ST-246 on the production of infectious particles in primary lesions
after tail scariﬁcation. BALB/c mice (n = 6) were infected with 1  106 PFU of
puriﬁed CTGV or VACV-WR by tail scariﬁcation. ST-246 at 50 or 100 mg/kg was
administered by oral gavage for 5 days when mice were euthanized for removal of
the primary lesions. Virus yields were determined by plaque assay of the tissue
extracts and normalized by protein concentration. Asterisks: p < 0.001 (one-way
Anova followed by Donnett’s and Tukey’s tests).
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tibility of CTGV to ST-246.4. Discussion
The pustulovesicular disease caused by Cantagalo virus in dairy
cows and dairy workers was initially detected in Rio de Janeiro
state and neighboring states of Southeastern Brazil (Damaso
et al., 2000, 2007; Nagasse-Sugahara et al., 2004). Recent reports
show that CTGV infection has spread to distant regions, including
the Amazon region, with an increasing number of human cases
(Medaglia et al., 2009; Quixabeira-Santos et al., 2011). This emerg-
ing viral zoonosis has signiﬁcant agricultural and occupational im-
pacts, and the implementation of an effective antiviral therapy
associated with an efﬁcient surveillance of animal trade would cer-
tainly help to reduce these effects.
The results obtained in this study demonstrate that ST-246 has
potent antiviral activity against CTGV replication. The EC50 values
found for CTGV in plaque-reduction assays were signiﬁcantly low-
er than the values obtained for other VACV strains and cowpox
virus. Similar dose–response curves were observed for different
ﬁeld isolates of CTGV collected during outbreaks in different states
of Brazil from 2000 to 2008, indicating that the increased suscep-
tibility to ST-246 is a well-preserved genetic feature of this ﬁeld
strain of VACV. All clinical isolates share the small-plaque pheno-
type observed for CTGV reference isolate CM-01 (data not shown),
which is clearly in line with the poor spread of CTGV infection incell culture. This inefﬁcient dissemination of CTGV could be evalu-
ated not only by the reduced size of the CTGV plaques, but also by
the diminished formation of comet tails during CTGV infection and
lower rates of virus replication when compared with those pro-
duced by VACV-WR. Under these circumstances, production of
intracellular and extracellular CTGV particles was nearly 1 log low-
er than VACV-WR yields.
Poor dissemination of CTGV infection was also observed in vivo.
Tail scariﬁcation assays produced less severe primary lesions and
few satellite lesions were rarely detected along the tail in contrast
to the infection with VACV-WR. CTGV doses 100 times higher than
those of VACV-WR did not increase virus dissemination. In these
in vivo assays, ST-246 was clearly more effective in inhibiting CTGV
replication than it was for VACV-WR. Doses of ST-246 above
25 mg/kg efﬁciently inhibited the dissemination of VACV-WR to
secondary sites of replication on the tail (satellite lesions), but
hadmild effect on the severity of the primary lesions. Nevertheless,
a signiﬁcant reduction of the primary lesions generated by CTGV
was observed in animals treated with P25 mg/kg ST-246. At
100 mg/kg, ST-246 prevented the formation of CTGV lesions. Titra-
tion of virus yields at the site of the primary lesions conﬁrmed
these visual observations.
F13 protein (p37) has been reported to be the target of ST-246
antiviral effect (Duraffour et al., 2008; Yang et al., 2005). This viral
protein is located to the TGN/endosomal membranes and is re-
quired for the wrapping of intracellular mature virions (MVs)
(Blasco and Moss, 1991; Roper and Moss, 1999). It has been shown
that ST-246 prevents p37 interaction with endosomal proteins
such as Tip47 and Rab9 thus blocking the formation of wrapped
virus (WV) (Chen et al., 2009). F13 ortholog from CTGV has a
D217N polymorphism not found in p37 from other orthopoxvirus-
es. Nonetheless, we were not able to associate this polymorphism
with the increased sensitivity of CTGV to ST-246. The EC50 values
found for WT VACV-WR in these assays were lower than those pre-
viously obtained in Table 1 and may be related to differences in the
cell culture conditions and quantiﬁcation methods as well as time
of ST-246 treatment. Moreover, recombinant viruses expressing
p37 with D217N did not show an increase in susceptibility to the
effect of the drug compared with WT virus. On the contrary, both
isolates of recombinant virus were more resistant to the inhibitory
effect of ST-246 on CPE-reduction assays or showed similar levels
of susceptibility to the drug in yield reduction assays and virus pla-
que reduction assays. Therefore, the mechanisms underlying the
increased susceptibility of CTGV to the effect of ST-246 are still un-
der investigation. However, it is plausible that the increased sus-
ceptibility of CTGV to ST-246 could be related to the reduced
ability of CTGV to disseminate in cell culture and in animals. Be-
cause ST-246 targets the process of virus egress and consequently,
virus dissemination, viruses deﬁcient in the process of dissemina-
tion could potentially be more affected by ST-246 in successive
rounds of virus multiplication.
So far, FK-506, brequinar, cidofovir (CDV) and treazole deriva-
tives have been the only drugs reported to present antiviral activity
against CTGV (Jesus et al., 2009b; Jordao et al., 2009; Reis et al.,
2006; Schnellrath and Damaso, 2011). Nevertheless, FK-506 and
brequinar are immunosuppressive drugs, which is concerning.
While systemic CDV administration in humans has been associated
with use limiting toxicities, new oral prodrugs of CDV (CMX001)
have been developed that appear safe and well tolerated in hu-
mans and active against poxvirus infections in vivo (Kern et al.,
2002; Painter et al., 2012; Quenelle et al., 2004b).
Given the nature of CTGV infections, topical application of anti-
viral drugs to the teats and udders of infected cattle and use of
latex gloves by workers could potentially limit spread of CTGV
and reduce disease burden. Topical formulations of CDV have been
used for treating cutaneous lesions caused by orthopoxviruses
Fig. 7. D217N polymorphism in F13 is not associated with the increased sensitivity of CTGV to ST-246. (A) Multiple alignment of the partial amino acid sequences of F13
orthologs in different orthopoxviruses. The yellow box indicates the YPPL motif; the grey box indicates the palmitoylation site; the blue box indicates the D217N
polymorphism present only in F13 sequence from CTGV; the pink box indicate the resistance site for ST-246; the green box indicates the KHD motif. (B) BSC-40 cells were
infected with two different isolates (#B and #C) of recombinant VACV-WR expressing the D217 amino acid substitution or the wild-type (WT) VACV-WR in the presence of 24
different concentrations of ST-246 varying from 0.001 to 5 lM. After 72 h post-infection, the cells were stained with crystal violet and CPE was quantiﬁed by OD reading.
Mock indicates non-infected cells. (C) BSC-40 cells were infected with 100 PFU of isolates #B and # C of VACV-WR orWT virus and were either treated with 0.05 lM ST-246 or
with 0.1% DMSO (control). Plaques were stained with crystal violet after 48 h post-infection. Representative images of at least 3 independent assays are shown in (B) and (C).
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 3
Effect of ST-246 on the replication of VACV-WR expressing mutated F13.
Virus CPE-reduction assay Yield-reduction assay Plaque-reduction assay
EC50 (lM)a SIb EC50 (lM)a SIb % inhibitiona,c % inhibitiona,c
VACV-WR 0.033 ± 0.002 >3,030 0.013 ± 0.002 >7,692 76.34 ± 8.59 40.0 ± 7.21
VACV-WR
D217N #B
0.064 ± 0.006d >1,563 0.022 ± 0.012f >4,545 61.97 ± 7.87 f 32.3 ± 12.15f
VACV-WR
D217N #C
0.075 ± 0.038e >1,333 0.021 ± 0.010f >4,762 65.50 ± 1.81 f 20.6 ± 14.57f
a The values represent the mean of at least 3 independent assays ± standard deviations.
b The selective index for each virus was determined as the ratio CC50/EC50, where CC50 was estimated to be >100 lM.
c Values correspond to the % inhibition in the presence of 0.05 lM ST-246.
d p < 0.01 (one-way Anova followed by Donnett’s and Tukey’s tests) relative to control group VACV-WR.
e p < 0.001 (one-way Anova followed by Donnett’s and Tukey’s tests) relative to control group VACV-WR.
f p > 0.05 (one-way Anova followed by Donnett’s and Tukey’s tests) relative to control group VACV-WR.
310 É. Santos-Fernandes et al. / Antiviral Research 97 (2013) 301–311(Quenelle et al., 2004a). While ST-246 has not been formulated as a
topical antiviral it would be interesting to test its efﬁcacy in vivo
when ST-246 was applied topically on CTGV lesions alone and in
combination with CDV.Acknowledgments
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